ArticleCirculation2024
Novel Mouse Model of Myocardial Infarction, Plaque Rupture, and Stroke Shows Improved Survival With Myeloperoxidase Inhibition.
Abstract read
In one paragraph
Article in Circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Systemic inflammation increases mast cell numbers in coronary arteries in patients who died from myocardial infarction.Journal of molecular and cellular cardiology plus · 2026Article
- Precision inflammation targeting via myeloperoxidase mediated antioxidant melanin nanomedicines for chronic inflammation therapy.Nature communications · 2026Article
- A Framework for Selecting Zebrafish Models of Metabolic Diseases: Modeling Strategies, Phenotypic Validation, Mechanistic Investigation, and Efficacy Evaluation.Biomedicines · 2026Review
- Heparanase gene deficiency suppresses atherosclerosis progression and enhances plaque stability in apolipoprotein E gene knockout mice with diabetes.Clinical science (London, England : 1979) · 2026Article
- Endothelial Estrogen Receptor Alpha Inhibits Plaque Inflammation in Both Sexes.Circulation research · 2026Article
- Heart-homed nanomedicine induces fast mitochondrial rescue to enhance cardiac function post-myocardial infarction.Bioactive materials · 2026Article
- Neutrophil extracellular traps in the tumor microenvironment, metastasis, therapy, and beyond: advances, challenges, and perspectives.Journal of hematology & oncology · 2026Review
- Considerations in the Use of Mouse Models of Vascular and Valvular Calcification.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Establishment of a mouse model for ischaemic heart failure induced by coronary microembolization via left ventricular oil injection.Experimental physiology · 2026Article
- Logic-gated fluorescent biosensor integrating aptamer recognition and oxidative cleavage-responsive DNA circuit for myeloperoxidase detection.Journal of translational medicine · 2026Article
- Developing a carotid ultrasound radiomics-semantic fusion model to identify aortic dissection: a two-center retrospective study.Frontiers in medicine · 2026Article
- Cell-derived biomimetic nanomedicines: Emerging theranostic platforms for precision management of atherosclerosis.Theranostics · 2026Review
- Zebrafish model for studying vascular development and vascular-related disease.Frontiers in cell and developmental biology · 2026Review
- Bambi/Akt/Tlr4 axis protects against atherosclerosis by maintaining lipid metabolism homeostasis in macrophages.Lipids in health and disease · 2025Article
- Neutrophil Extracellular Traps (NETs) in health and disease.Molecular biomedicine · 2025Review
- Smooth muscle cells in atherosclerosis: essential but overlooked translational perspectives.European heart journal · 2025Review
- Exploiting the 2-(1,3,4,9-tetrahydropyrano[3,4-Journal of medicinal chemistry · 2025Article
- Macrophage DNases Limit Neutrophil Extracellular Trap-Mediated Defective Efferocytosis in Atherosclerosis.Circulation research · 2025Article
- Atherosclerotic Plaque Instability and Rupture: Recommended Mouse Models to Empower Clinically Relevant Discoveries, Diagnostics, and Therapeutics.Arteriosclerosis, thrombosis, and vascular biology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
21 authors.
Sohel Shamsuzzaman *Robert M. Berne Cardiovascular Research Center (S. Shamsuzzaman, R.A.D., A.S., V.S., V.M.M., S.K. S. Saibaba, L.S.S., G.K.O.), University of Virginia School of Medicine, Charlottesville.ORCID 0000-0003-2033-8976
Rebecca A Deaton *Robert M. Berne Cardiovascular Research Center (S. Shamsuzzaman, R.A.D., A.S., V.S., V.M.M., S.K. S. Saibaba, L.S.S., G.K.O.), University of Virginia School of Medicine, Charlottesville.ORCID 0000-0001-7569-1924
Anita SalamonRobert M. Berne Cardiovascular Research Center (S. Shamsuzzaman, R.A.D., A.S., V.S., V.M.M., S.K. S. Saibaba, L.S.S., G.K.O.), University of Virginia School of Medicine, Charlottesville.ORCID 0000-0002-5708-9494
Heather DoviakHematovascular Biology Center, Robert M. Berne Cardiovascular Research Center (H.D., M.A.E., K.W., S.B.), University of Virginia School of Medicine, Charlottesville.ORCID 0000-0002-0720-3164
Vlad SerbuleaRobert M. Berne Cardiovascular Research Center (S. Shamsuzzaman, R.A.D., A.S., V.S., V.M.M., S.K. S. Saibaba, L.S.S., G.K.O.), University of Virginia School of Medicine, Charlottesville.ORCID 0000-0002-9988-4410
Victoria M MilosekRobert M. Berne Cardiovascular Research Center (S. Shamsuzzaman, R.A.D., A.S., V.S., V.M.M., S.K. S. Saibaba, L.S.S., G.K.O.), University of Virginia School of Medicine, Charlottesville.ORCID 0000-0003-3520-9931
Megan A EvansHematovascular Biology Center, Robert M. Berne Cardiovascular Research Center (H.D., M.A.E., K.W., S.B.), University of Virginia School of Medicine, Charlottesville.ORCID 0000-0002-7338-3060
Santosh KarnewarRobert M. Berne Cardiovascular Research Center (S. Shamsuzzaman, R.A.D., A.S., V.S., V.M.M., S.K. S. Saibaba, L.S.S., G.K.O.), University of Virginia School of Medicine, Charlottesville.ORCID 0000-0001-7941-297X
Subhi SaibabaRobert M. Berne Cardiovascular Research Center (S. Shamsuzzaman, R.A.D., A.S., V.S., V.M.M., S.K. S. Saibaba, L.S.S., G.K.O.), University of Virginia School of Medicine, Charlottesville.
Gabriel F AlencarBeirne B. Carter Center for Immunology Research (G.F.A.), University of Virginia School of Medicine, Charlottesville.ORCID 0000-0002-1752-7429
Laura S ShankmanRobert M. Berne Cardiovascular Research Center (S. Shamsuzzaman, R.A.D., A.S., V.S., V.M.M., S.K. S. Saibaba, L.S.S., G.K.O.), University of Virginia School of Medicine, Charlottesville.ORCID 0000-0003-4983-9467
Kenneth WalshDepartment of Biochemistry and Molecular Genetics (A.S., K.W.), University of Virginia School of Medicine, Charlottesville.ORCID 0000-0001-7580-2276
Stefan BekiranovHematovascular Biology Center, Robert M. Berne Cardiovascular Research Center (H.D., M.A.E., K.W., S.B.), University of Virginia School of Medicine, Charlottesville.ORCID 0000-0002-3177-4346
Olivier KocherDepartment of Pathology and Center for Vascular Biology Research, Beth Israel Medical Deaconess Medical Center Harvard Medical School, Boston, MA (O.K.).
Monty KriegerDepartment of Biology, Massachusetts Institute of Technology, Cambridge (M.K.).ORCID 0000-0003-4541-5181
Bengt KullBioPharmaceuticals R&D Early Cardiovascular Renal and Metabolism (CVRM) Bioscience Cardiovascular, AstraZeneca, Mölndal, Sweden (B.K.).
Marie PerssonBioPharmaceuticals R&D Early Cardiovascular Renal and Metabolism (CVRM) DMPK, AstraZeneca, Mölndal, Sweden (M.P.).ORCID 0000-0002-5126-5733
Erik MichaëlssonEarly Clinical Development, Research and Early Development, Cardiovascular, Renal, and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (E.M.).ORCID 0000-0001-8643-2821
Nils BergenhemAlliance Management, Business Development & Licensing, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA (N.B.).
Sepideh Heydarkhan-HagvallAstraZeneca R&D, Chief Medical Office, Global Patient Safety, Mölndal, Sweden (S.H.-H.).
Gary K OwensRobert M. Berne Cardiovascular Research Center (S. Shamsuzzaman, R.A.D., A.S., V.S., V.M.M., S.K. S. Saibaba, L.S.S., G.K.O.), University of Virginia School of Medicine, Charlottesville.ORCID 0000-0002-7119-9657
Funding
BASIC CARDIOVASCULAR RESEARCH TRAINING GRANTT32HL007284 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Brant E Isakson, Gary K Owens · 1985 to 2026
$19.6MRole of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesisR01HL164367 · NHLBI · UNIVERSITY OF VIRGINIA · PI Gary K Owens · 2023 to 2026
$3.2MRole of Smooth Muscle Cell Insulin Resistance and Systemic Metabolic Dysfunction in Atherosclerosis Development and Late Stage Lesion PathogenesisR01HL166161 · NHLBI · UNIVERSITY OF VIRGINIA · PI Gary K Owens · 2023 to 2026
$3.2MEndothelial Cell to Mesenchymal Cell Transitions Play a Critical Biological Sex- and Aging-Dependent Role in Formation and Maintenance of the Acta2+ Atherosclerotic Lesion Protective Fibrous CapR01HL156849 · NHLBI · UNIVERSITY OF VIRGINIA · PI OWENS, GARY K · 2022 to 2025
$3.2MIL1beta signaling in SMCpromotes beneficial changes in late stage atherosclerotic lesion pathogenesisR01HL141425 · NHLBI · UNIVERSITY OF VIRGINIA · PI OWENS, GARY K · 2019 to 2022
$3.1MDefining SMC phenotypes critical in late stage atherosclerosis pathogenesisR01HL136314 · NHLBI · UNIVERSITY OF VIRGINIA · PI OWENS, GARY K · 2018 to 2021
$3.0MRole of Metabolic Reprogramming in Formation and Maintenance of the Acta2+ Atherosclerotic Lesion Protective Fibrous CapR01HL155165 · NHLBI · UNIVERSITY OF VIRGINIA · PI OWENS, GARY K · 2021 to 2024
$2.9MCanonical & non-canonical regulation of the HDL receptor by PDZK1's PDZ domainsR01HL127174 · NHLBI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KRIEGER, MONTY · 2016 to 2019
$1.9MNHLBI NIH HHS R01 HL127174NHLBI NIH HHS R01 HL136314NHLBI NIH HHS R01 HL141425NHLBI NIH HHS R01 HL155165NHLBI NIH HHS R01 HL156849NHLBI NIH HHS R01 HL164367NHLBI NIH HHS R01 HL166161NHLBI NIH HHS T32 HL007284
Abstract
backgroundThromboembolic events, including myocardial infarction (MI) or stroke, caused by the rupture or erosion of unstable atherosclerotic plaques are the leading cause of death worldwide. Although most mouse models of atherosclerosis develop lesions in the aorta and carotid arteries, they do not develop advanced coronary artery lesions. Moreover, they do not undergo spontaneous plaque rupture with MI and stroke or do so at such a low frequency that they are not viable experimental models to study late-stage thrombotic events or to identify novel therapeutic approaches for treating atherosclerotic disease. This has stymied the development of more effective therapeutic approaches for reducing these events beyond what has been achieved with aggressive lipid lowering. Here, we describe a diet-inducible mouse model that develops widespread advanced atherosclerosis in coronary, brachiocephalic, and carotid arteries with plaque rupture, MI, and stroke.
methodsWe characterized a novel mouse model with a C-terminal mutation in the scavenger receptor class B, type 1 (SR-BI), combined with
resultsSR-BI
conclusionsWD-fed SR-BI
Indexed as
Myocardial InfarctionPeroxidasePlaque, AtheroscleroticStrokeAnimalsDiet, WesternDisease Models, AnimalEnzyme InhibitorsMaleMiceMice, Inbred C57BLMice, KnockoutReceptors, LDLRupture, SpontaneousScavenger Receptors, Class BEnzyme InhibitorsPeroxidaseReceptors, LDLScarb1 protein, mouseScavenger Receptors, Class Batherosclerosiscoronary diseasemicemyocardial infarctionperoxidaserupturestroke
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.